ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi and Regeneron Pharmaceuticals have paid BioMarin $67.5 million for a voucher that will speed up FDA review of alirocumab, a monoclonal antibody the two are developing as a cholesterol-lowering agent. Under a 2012 law, FDA issues such vouchers to firms that develop drugs for rare pediatric diseases. BioMarin obtained its voucher in February when it won approval of Vimizim, which treats Morquio A syndrome, a rare pediatric disease. With the voucher, Sanofi and Regeneron will enjoy a six-month review instead of the standard 10-month review. The sale is the first for the pediatric priority review voucher program.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter